Claudia Stefanutti

List of Publications by Year
in descending order

110	3,107	186265	175258
papers	citations	28 h-index	52 g-index

124	124	124	2704
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients With Diabetes. Clinical Therapeutics, 2022, 44, 331-348.	2.5	4
2	The impact of type of dietary protein, animal versus vegetable, in modifying cardiometabolic risk factors: A position paper from the International Lipid Expert Panel (ILEP). Clinical Nutrition, 2021, 40, 255-276.	5.0	75
3	Current Approach to the Diagnosis and Treatment of Heterozygote and Homozygous FH Children and Adolescents. Current Atherosclerosis Reports, 2021, 23, 30.	4.8	19
4	Risk Assessment and Clinical Management of Children and Adolescents with Heterozygous Familial Hypercholesterolaemia. A Position Paper of the Associations of Preventive Pediatrics of Serbia, Mighty Medic and International Lipid Expert Panel. Journal of Clinical Medicine, 2021, 10, 4930.	2.4	10
5	Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia. JAMA Cardiology, 2020, 5, 217.	6.1	169
6	Lipoprotein(a) concentration, genetic variants, apo(a) isoform size, and cellular cholesterol efflux in patients with elevated Lp(a) and coronary heart disease submitted or not to lipoprotein apheresis: An Italian case-control multicenter study on Lp(a). Journal of Clinical Lipidology, 2020, 14, 487-497.e1.	1.5	17
7	Lipid profile and left ventricular geometry pattern in obese children. Lipids in Health and Disease, 2020, 19, 109.	3.0	12
8	Lomitapideâ€“a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia. Current Atherosclerosis Reports, 2020, 22, 38.	4.8	33
9	Homozygous familial hypercholesterolaemia in childhood â€“ The first case report in Southeast Europe. Atherosclerosis Supplements, 2019, 40, 122-124.	1.2	2
10	Looking at Lp(a) and Related Cardiovascular Risk: from Scientific Evidence and Clinical Practice. Current Atherosclerosis Reports, 2019, 21, 37.	4.8	15
11	A cross-national investigation of cardiovascular survival in homozygous familial hypercholesterolemia: The Sino-Roman Study. Journal of Clinical Lipidology, 2019, 13, 608-617.	1.5	22
12	Efficacy and safety of PCSK9 monoclonal antibodies. Expert Opinion on Drug Safety, 2019, 18, 1191-1201.	2.4	16
13	A successful term pregnancy with severe hypertriglyceridaemia and acute pancreatitis. Clinical management and review of the literature. Atherosclerosis Supplements, 2019, 40, 117-121.	1.2	7
14	A complicated pregnancy in homozygous familial hypercholesterolaemia treated with lipoprotein apheresis: A case report. Atherosclerosis Supplements, 2019, 40, 113-116.	1.2	2
15	Lipoprotein Apheresis and PCSK9-Inhibitors. Impact on Atherogenic Lipoproteins and Anti-Inflammatory Mediators in Familial Hypercholesterolaemia. Current Pharmaceutical Design, 2019, 24, 3634-3637.	1.9	8
16	Optical coherence tomography of retinal and choroidal layers in patients with familial hypercholesterolaemia treated with lipoprotein apheresis. Atherosclerosis Supplements, 2019, 40, 49-54.	1.2	10
17	Serum uric acid and left ventricular geometry pattern in obese children. Atherosclerosis Supplements, 2019, 40, 88-93.	1.2	7
18	Evolocumab and lipoprotein apheresis combination therapy may have synergic effects to reduce lowâ€density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemia: A case report. Journal of Clinical Apheresis, 2018, 33, 546-550.	1.3	5

#	Article	IF	Citations
19	Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia. Journal of Clinical Lipidology, 2018, 12, 390-396.e8.	1.5	51
20	Characterisation of patients with familial chylomicronaemia syndrome (FCS) and multifactorial chylomicronaemia syndrome (MCS): Establishment of an FCS clinical diagnostic score. Data in Brief, 2018, 21, 1334-1336.	1.0	4
21	LDL-C Therapeutic Target Attainment in Patients with Homozygous Familial Hypercholesterolemia treated with Lomitapide. Atherosclerosis Supplements, 2018, 32, 153-154.	1.2	0
22	Hypercholesterolaemia â€“ practical information for non-specialists. Archives of Medical Science, 2018, 1, 1-21.	0.9	39
23	Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an â€œFCS scoreâ€. Atherosclerosis, 2018, 275, 265-272.	0.8	131
24	Toward an international consensusâ€”Integrating lipoprotein apheresis and new lipid-lowering drugs. Journal of Clinical Lipidology, 2017, 11, 858-871.e3.	1.5	105
25	Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia. Journal of Clinical Lipidology, 2017, 11, 1448-1457.	1.5	48
26	Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia. Journal of Clinical Lipidology, 2017, 11, 1338-1346.e7.	1.5	38
27	Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholesterolemia. Circulation, 2017, 136, 332-335.	1.6	103
28	Lipoprotein apheresis downregulates IL-1Î±, IL-6 and TNF-Î± mRNA expression in severe dyslipidaemia. Atherosclerosis Supplements, 2017, 30, 200-208.	1.2	16
29	Monascus purpureus for statin and ezetimibe intolerant heterozygous familial hypercholesterolaemia patients: A clinical study. Atherosclerosis Supplements, 2017, 30, 86-91.	1.2	10
30	The 1 and the 2 Italian Consensus Conferences on low-density lipoprotein-apheresis. A practical synopsis and update. Blood Transfusion, 2017, 15, 42-48.	0.4	6
31	Relationship between Sustained Reductions in Plasma Lipid and Lipoprotein Concentrations with Apheresis and Plasma Levels and mRNA Expression of PTX3 and Plasma Levels of hsCRP in Patients with HyperLp(a)lipoproteinemia. Mediators of Inflammation, 2016, 2016, 1-8.	3.0	9
32	ODYSSEY ESCAPE: is PCSK9 inhibition the Trojan Horse for the use of lipoprotein apheresis in familial hypercholesterolaemia?. European Heart Journal, 2016, 37, 3596-3599.	2.2	13
33	Management of homozygous familial hypercholesterolemia in real-world clinical practice: A report of 7 Italian patients treatedÂinÂRome with lomitapide and lipoproteinÂapheresis. Journal of Clinical Lipidology, 2016, 10, 782-789.	1.5	27
34	Therapeutic Apheresis in Pregnancy: Three Differential Indications With Positive Maternal and Fetal Outcome. Therapeutic Apheresis and Dialysis, 2016, 20, 677-685.	0.9	8
35	Lipoprotein apheresis is essential for managing pregnancies in patients with homozygous familial hypercholesterolemia: Seven case series and discussion. Atherosclerosis, 2016, 254, 179-183.	0.8	26
36	Individual analysis of patients with HoFH participating in a phase 3 trial with lomitapide: The Italian cohort. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 36-44.	2.6	16

#	Article	IF	Citations
37	Scientific Information Security in Information Science and Academic Publishing. Artificial Organs, 2016, 40, 425-430.	1.9	1
38	Supplementation with coenzyme Q10 reduces plasma lipoprotein(a) concentrations but not other lipid indices: A systematic review and meta-analysis. Pharmacological Research, 2016, 105, 198-209.	7.1	53
39	HyperLp(a)lipoproteinaemia: unmet need of diagnosis and treatment?. Blood Transfusion, 2016, 14, 408-12.	0.4	6
40	Geometric complexity identifies platelet activation in familial hypercholesterolemic patients. Microscopy Research and Technique, 2015, 78, 519-522.	2.2	3
41	Homozygous autosomal dominant hypercholesterolaemia. Current Opinion in Lipidology, 2015, 26, 200-209.	2.7	52
42	Treatment of primary hypertriglyceridemia states â€“ General approach and the role of extracorporeal methods. Atherosclerosis Supplements, 2015, 18, 85-94.	1.2	17
43	Lipoprotein Apheresis in the Management of Familial Hypercholesterolaemia: Historical Perspective and Recent Advances. Current Atherosclerosis Reports, 2015, 17, 465.	4.8	53
44	The effect of an apolipoprotein A-Iâ€“containing high-density lipoproteinâ€“mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia. American Heart Journal, 2015, 169, 736-742.e1.	2.7	59
45	Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/kexin typeÂ9. Clinical Science, 2015, 129, 63-79.	4.3	21
46	First on-line survey of an international multidisciplinary working group (MightyMedic) on current practice in diagnosis, therapy and follow-up of dyslipidemias. Atherosclerosis Supplements, 2015, 18, 241-250.	1.2	5
47	The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia â€“ A post-hoc analysis of a Phase 3, single-arm, open-label trial. Atherosclerosis, 2015, 240, 408-414.	0.8	36
48	Efficacy and Safety of Pitavastatin in Children and Adolescents at High Future Cardiovascular Risk. Journal of Pediatrics, 2015, 167, 338-343.e5.	1.8	40
49	Hijacked journals are emerging as a challenge for scholarly publishing. Polish Archives of Internal Medicine, 2015, 125, 783-784.	0.4	3
50	Effects of CER-001 on carotid atherosclerosis by 3tmri in homozygous familial hypercholesterolemia (HoFH): The modifying orphan disease evaluation (mode) study. Atherosclerosis, 2014, 235, e13-e14.	0.8	3
51	Targeting MTP for the treatment of homozygous familial hypercholesterolemia. Clinical Lipidology, 2014, 9, 369-381.	0.4	3
52	Misfolding of Apoprotein B-100, LDL Aggregation and 17-β -estradiol in Atherogenesis. Current Medicinal Chemistry, 2014, 21, 2276-2283.	2.4	10
53	Hypertriglyceridaemia, Postprandial Lipaemia and Non-HDL Cholesterol. Current Pharmaceutical Design, 2014, 20, 6238-6248.	1.9	15
54	Severe Hypertriglyceridemiaâ€Related Acute Pancreatitis. Therapeutic Apheresis and Dialysis, 2013, 17, 130-137.	0.9	88

#	Article	IF	Citations
55	Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet, The, 2013, 381, 40-46.	13.7	624
56	Lipoprotein apheresis: State of the art and novelties. Atherosclerosis Supplements, 2013, 14, 19-27.	1.2	64
57	A three month-old infant with severe hyperchylomicronemia: Molecular diagnosis and extracorporeal treatment. Atherosclerosis Supplements, 2013, 14, 73-76.	1.2	25
58	Italian Multicenter Study on Lowâ€Density Lipoprotein Apheresis Working Group 2009 Survey. Therapeutic Apheresis and Dialysis, 2013, 17, 169-178.	0.9	14
59	Severe Hypertriglyceridemiaâ€Related Acute Pancreatitis: Myth or Reality?. Therapeutic Apheresis and Dialysis, 2013, 17, 464-465.	0.9	3
60	Treatment of Severe Genetic Dyslipidemia: Where Are We Going?. Therapeutic Apheresis and Dialysis, 2013, 17, 122-123.	0.9	5
61	Multiple Lipid-lowering Treatment in Pediatric Patients with Hyperlipidemia. Medicinal Chemistry, 2012, 8, 1171-1181.	1.5	5
62	New Clinical Perspectives of Hypolipidemic Drug Therapy in Severe Hypercholesterolemia. Current Medicinal Chemistry, 2012, 19, 4861-4868.	2.4	23
63	Multiple Lipid-lowering Treatment in Pediatric Patients with Hyperlipidemia. Medicinal Chemistry, 2012, 8, 1171-1181.	1.5	5
64	Cytokines profile in serum of homozygous familial hypercholesterolemia is changed by LDL-apheresis. Cytokine, 2011, 55, 245-250.	3.2	30
65	Apheresis-inducible cytokine pattern change in severe, genetic dyslipidemias. Cytokine, 2011, 56, 835-841.	3.2	13
66	Lipid and low-density-lipoprotein apheresis. Effects on plasma inflammatory profile and on cytokine pattern in patients with severe dyslipidemia. Cytokine, 2011, 56, 842-849.	3.2	41
67	Effects of selective H.E.L.P. LDL-apheresis on plasma inflammatory markers concentration in severe dyslipidemia: Implication for anti-inflammatory response. Cytokine, 2011, 56, 850-854.	3.2	19
68	Timing clinical events in the treatment of pancreatitis and hypertriglyceridemia with therapeutic plasmapheresis. Transfusion and Apheresis Science, 2011, 45, 3-7.	1.0	36
69	Italian Multicenter Study on Lowâ€Density Lipoprotein Apheresis: Retrospective Analysis (2007). Therapeutic Apheresis and Dialysis, 2010, 14, 79-86.	0.9	8
70	The 2009 2nd Italian Consensus Conference on LDL-apheresis. Nutrition, Metabolism and Cardiovascular Diseases, 2010, 20, 761-762.	2.6	20
71	Treatment of symptomatic hyperLp(a)lipidemia with LDL-apheresis vs. usual care. Transfusion and Apheresis Science, 2010, 42, 21-26.	1.0	29
72	The Italian registry of pediatric therapeutic apheresis: A report on activity during 2005. Journal of Clinical Apheresis, 2009, 24, 1-5.	1.3	33

#	Article	IF	Citations
73	Immunoadsorption apheresis and immunosuppressive drug therapy in the treatment of complicated HCVâ€related cryoglobulinemia. Journal of Clinical Apheresis, 2009, 24, 241-246.	1.3	29
74	Combined Treatment with Dif1stat^{Â®} and Diet Reduce Plasma Lipid Indicators of Moderate Hypercholesterolemia More Effectively than Diet Alone: A Randomized Trial in Parallel Groups. Lipids, 2009, 44, 1141-8.	1.7	12
75	Clinical Trials in Apheresis. Therapeutic Apheresis and Dialysis, 2009, 13, 171-173.	0.9	0
76	Aorta and coronary angiographic followâ€up of children with severe hypercholesterolemia treated with lowâ€density lipoprotein apheresis. Transfusion, 2009, 49, 1461-1470.	1.6	30
77	Therapeutic Plasma Exchange in Patients With Severe Hypertriglyceridemia: A Multicenter Study. Artificial Organs, 2009, 33, 1096-1102.	1.9	67
78	LDL Apheresis: A Novel Technique (LIPOCOLLECT 200). Artificial Organs, 2009, 33, 1103-1108.	1.9	8
79	Treatment of symptomatic HyperLp(a)lipoproteinemia with LDL-apheresis: a multicentre study. Atherosclerosis Supplements, 2009, 10, 89-94.	1.2	19
80	Effects of Low-Dose Atorvastatin and Rosuvastatin on Plasma Lipid Profiles. American Journal of Cardiovascular Drugs, 2008, 8, 265-270.	2.2	13
81	Hypercholesterolaemia alters the responses of the plasma lipid profile and inflammatory markers to supplementation of the diet with n-3 polyunsaturated fatty acids from fish oil. European Journal of Clinical Investigation, 2006, 36, 788-795.	3.4	9
82	Cyclophosphamide and Immunoadsorption Apheresis Treatment of Lupus Nephritis Nonresponsive to Drug Therapy Alone. BioDrugs, 2005, 19, 129-133.	4.6	7
83	Efficacy, Safety and Tolerability of???Combined Low-Dose Simvastatin-Fenofibrate Treatment in Primary Mixed Hyperlipidaemia. Clinical Drug Investigation, 2004, 24, 465-477.	2.2	13
84	Therapeutic apheresis in low weight patients: technical feasibility, tolerance, compliance, and risks. Transfusion and Apheresis Science, 2004, 31, 3-10.	1.0	43
85	Immunoadsorption apheresis (SelesorbÂ©) in the treatment of chronic hepatitis C virus-related type 2 mixed cryoglobulinemia. Transfusion and Apheresis Science, 2003, 28, 207-214.	1.0	17
86	Acute and long-term effects of low-density lipoprotein (LDL)-apheresis on oxidative damage to LDL and reducing capacity of erythrocytes in patients with severe familial hypercholesterolaemia. Clinical Science, 2001, 100, 191-198.	4.3	21
87	Acute and long-term effects of low-density lipoprotein (LDL)-apheresis on oxidative damage to LDL and reducing capacity of erythrocytes in patients with severe familial hypercholesterolaemia. Clinical Science, 2001, 100, 191.	4.3	9
88	DALI Low-Density Lipoprotein Apheresis in Homozygous and Heterozygous Familial Hypercholesterolemic Patients Using Low-Dose Citrate Anticoagulation. Therapeutic Apheresis and Dialysis, 2001, 5, 364-371.	0.9	6
89	Low-density lipoprotein apheresis in a patient aged 3.5 years. Acta Paediatrica, International Journal of Paediatrics, 2001, 90, 694-701.	1.5	24
90	Lowâ€density lipoprotein apheresis in a patient aged 3.5 years. Acta Paediatrica, International Journal of Paediatrics, 2001, 90, 694-701.	1.5	1

#	Article	IF	Citations
91	Clinical Expression of Familial Hypercholesterolemia in Clusters of Mutations of the LDL Receptor Gene That Cause a Receptor-Defective or Receptor-Negative Phenotype. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, E41-52.	2.4	122
92	Diet only and diet plus simvastatin in the treatment of heterozygous familial hypercholesterolemia in childhood. Drugs Under Experimental and Clinical Research, 1999, 25, 23-8.	0.3	17
93	Comparison of Different Ldl-Apheresis Techniques. International Journal of Artificial Organs, 1998, 21, 66-71.	1.4	6
94	Effect of L-carnitine on plasma lipoprotein fatty acids pattern in patients with primary hyperlipoproteinemia. Clinica Terapeutica, 1998, 149, 115-9.	0.1	2
95	Pattern of red blood cells and platelets cholesterol and fatty acids in homozygous familial hypercholesterolemic patients treated with LDL-apheresis. Clinica Terapeutica, 1998, 149, 231-3.	0.1	0
96	Platelet Activation in Hypercholesterolemic Patients Submitted to Therapeutic Plasmapheresis. An Ultrastructural Study. Hematology, 1997, 2, 491-496.	1.5	0
97	4.P.411 Diet only and diet plus simvastatin in the treatment of heterozygous familial hypercholesterolemia in childhood. Atherosclerosis, 1997, 134, 383.	0.8	0
98	LDL Apheresis in a Homozygous Familial Hypercholesterolemic Child Aged 4.5. Artificial Organs, 1997, 21, 1126-1127.	1.9	13
99	A new treatment of refractory ascites: Ascitoapheresis. Journal of Clinical Apheresis, 1996, 11, 46-47.	1.3	0
100	Effect of oral and transdermal hormone replacement therapy on lipid profile and Lp(a) level in menopausal women with hypercholesterolemia. International Journal of Fertility and Menopausal Studies, 1996, 41, 509-15.	0.1	6
101	Association of Serum Selenium with Selected Cardiovascular Risk Factors. Microchemical Journal, 1995, 51, 170-180.	4.5	1
102	LDL-apheresis in pediatric patients with severe hyperlipoproteinemia. Journal of Clinical Apheresis, 1995, 10, 101-102.	1.3	5
103	Four Novel Partial Deletions of LDL-Receptor Gene in Italian Patients With Familial Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 81-88.	2.4	21
104	Treatment of Homozygous and Double Heterozygous Familial Hypercholesterolemia Children with LDL-Apheresis. International Journal of Artificial Organs, 1995, 18, 103-110.	1.4	18
105	Treatment of homozygous and double heterozygous familial hypercholesterolemic children with LDL-apheresis. International Journal of Artificial Organs, 1995, 18, 103-10.	1.4	4
106	A new missense mutation (Cys297?Phe) of the low density lipoprotein receptor in Italian patients with familial hypercholesterolemia (FHTrieste). Human Genetics, 1994, 93, 538-40.	3.8	5
107	Simvastatin and pravastatin: A daily dose of 40 mg in the long-term treatment of primary hypercholesterolemia. Current Therapeutic Research, 1994, 55, 446-454.	1.2	1
108	Chorionic DNA analysis for the prenatal diagnosis of familial hypercholesterolaemia. Human Genetics, 1993, 92, 424-426.	3.8	4

#	Article	IF	Citations
109	Lipoprotein and Hemocoagulatory Parameters during Therapeutic Plasmapheresis in Homozygous and Heterozygous Familial Hypercholesterolemia. , 1993, , 223-233.		0
110	Selective continuous removal of low density lipoproteins by dextran sulfate cellulose column adsorption apheresis in the therapy of familial hypercholesterolemia. BeitrÃge Zur Infusionstherapie = Contributions To Infusion Therapy, 1988, 23, 172-82.	0.0	0